低分子肝素钙治疗慢性肺源性心脏病急性加重期疗效观察

Clinical Observation of Low Molecular Heparin Calcium in the Treatment of Acute Exacerbation of Chronic Pulmonary Heart Disease

目的:探讨低分子肝素钙治疗慢性肺源性心脏病急性加重期的临床疗效。方法:78例慢性肺源性心脏病急性加重期患者随机分成两组,治疗组40例,对照组38例,两组均给予吸氧,控制感染,止咳平喘,改善心肺功能等常规治疗,治疗组在常规治疗基础上加用低分子肝素钙5 000IU腹部皮下注射,每日一次,共10d。观察两组临床疗效,动脉血气及血液流变学变化。结果:治疗组较对照组心肺功能明显改善,有效率达90%,对照组有效率71%,两组间有明显差异(P<0.05),治疗组红细胞压积,全血粘度,血浆粘度,纤维蛋白原,血沉明显降低,PaCO2降低,PO2增高。结论:低分子肝素钙治疗慢性肺源性心脏病急性加重期安全有效,值得临床推广。

Objective： To study the curative effect of low molecular heparin calcium in the treatment of acute exacerbation of chronic pulmonary heart disease. Method： 78 Patients who suffered from the acute exacerbation of chronic pulmonary heart disease were divided into the observation group （40cases） and the control group （38cases） by the random method. The two groups were given routine treatments, such as, axygen, antiinfection, cough-and-asthma-relieving, improvement of heart and lung function, etc. The observation group was given the routine treatment plus injection under the abdominal skin with 5000 IU low molecular heparin calcium per day for l 0 days as a course. Then, the clinical efficacy of the two groups, the blood gas and the hemorheology were observed. Result： The cardio pulmonary function of observation group was improved obviously. When the two groups were compared, it was found that the total effective rate was 90% in the observation group and 71% in the control group, There were significant differences between the two groups （P〈0.05）. The observation group has significantly decreased in hematocrit, total blood viscosity, plasma viscosity, fibrinogen and erythrocyte sedimentation; PaCO2 reduced and PO2 rose evidently. Conchlsion： Low molecular heparin calcium in treatment of acute exacerbation of chronic pulmonary heart disease is safe, effective and worth clinical application.